Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression

verfasst von: Yan Zhang, Haibo Wu, Man Zhang, Yali Jiang, Weiwei Zhuo, Yong Zhang, Song Hua

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to decide whether nicotinamide (NA) could induce apoptosis of F9 mouse teratocarcinoma stem cells (MF9) by downregulation of special AT-rich sequence binding protein 1 (SATB1) expression. We used different concentrations of NA (0, 1.5, 2, and 2.5 mmol/L) to treat MF9 cells and analyze SATB1 expression by RT-qPCR and Western blotting; in addition, the cell proliferation was detected in a microplate reader with Cell Counting Kit-8 (CCK-8), and the cell cycle and apoptosis were analyzed using flow cytometry. We found that the expression of SATB1 was decreased significantly in NA-treated groups than in the control group, and its expression level was inversely related to the NA concentration. In addition, CCK-8 analysis showed that NA significantly inhibited the proliferation of MF9 cells, and flow cytometry showed that NA blocked MF9 cells to G1 phase and significantly promoted apoptosis in any treated groups. To confirm the results, we constructed small interference RNA (siRNA) targeting at mouse SATB1 and transferred into MF9 cells. The results indicated that the expression of SATB1 in both mRNA and protein levels was significantly decreased after cells transferred with siRNA sequence for 48 h, the proliferation of MF9 cells was significantly inhibited, and most of MF9 cells were blocked at G1 phase, and the apoptosis rate was increased obviously. The results showed that NA could inhibit the proliferation and induce apoptosis of MF9 cells. These findings might be used as an efficient candidate for teratocarcinoma therapy.
Literatur
1.
Zurück zum Zitat Sonee M, Martens JR, Mukherjee SK. Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary-butylhydroperoxide (t-BuOOH). Neurotox Res. 2002;4:595–9.CrossRefPubMed Sonee M, Martens JR, Mukherjee SK. Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary-butylhydroperoxide (t-BuOOH). Neurotox Res. 2002;4:595–9.CrossRefPubMed
2.
Zurück zum Zitat Jin J, Lee KB, Park SY, Jang JJ. Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells. Virchows Arch. 2011;458:689–96.CrossRefPubMed Jin J, Lee KB, Park SY, Jang JJ. Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells. Virchows Arch. 2011;458:689–96.CrossRefPubMed
3.
Zurück zum Zitat Saldeen J, Tillmar L, Karlsson E, Welsh N. Nicotinamide-and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol Cell Biochem. 2003;243:113–22.CrossRefPubMed Saldeen J, Tillmar L, Karlsson E, Welsh N. Nicotinamide-and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol Cell Biochem. 2003;243:113–22.CrossRefPubMed
4.
Zurück zum Zitat Audrito V, Vaisitti T, Rossi D, Gottardi D, D’Arena G, Laurenti L, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011;71:4473–83.CrossRefPubMed Audrito V, Vaisitti T, Rossi D, Gottardi D, D’Arena G, Laurenti L, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011;71:4473–83.CrossRefPubMed
5.
Zurück zum Zitat Fernandes CA, Fievez L, Ucakar B, Neyrinck AM, Fillee C, Huaux F, et al. Nicotinamide enhances apoptosis of G(M)-CSF-treated neutrophils and attenuates endotoxin-induced airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300:L354–61.CrossRefPubMed Fernandes CA, Fievez L, Ucakar B, Neyrinck AM, Fillee C, Huaux F, et al. Nicotinamide enhances apoptosis of G(M)-CSF-treated neutrophils and attenuates endotoxin-induced airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2011;300:L354–61.CrossRefPubMed
6.
Zurück zum Zitat Luo JY, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137–48.CrossRefPubMed Luo JY, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137–48.CrossRefPubMed
7.
Zurück zum Zitat Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011–5.CrossRefPubMed Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011–5.CrossRefPubMed
8.
Zurück zum Zitat Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551–63.CrossRefPubMed Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116:551–63.CrossRefPubMed
9.
Zurück zum Zitat Hoane MR, Kaplan SA, Ellis AL. The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res. 2006;1125:185–93.CrossRefPubMed Hoane MR, Kaplan SA, Ellis AL. The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res. 2006;1125:185–93.CrossRefPubMed
10.
Zurück zum Zitat Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992;70:631–45.CrossRefPubMed Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992;70:631–45.CrossRefPubMed
11.
Zurück zum Zitat Shen ZH, Zeng YM, Guo JL, Wu YX, Jiang XF, Ding R, et al. Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J Transl Med. 2013. doi:10.1186/1479-5876-11-217. Shen ZH, Zeng YM, Guo JL, Wu YX, Jiang XF, Ding R, et al. Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J Transl Med. 2013. doi:10.​1186/​1479-5876-11-217.
12.
Zurück zum Zitat Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA, et al. Relationship between SATB1 expression and prognosis in astrocytoma. J Clin Neurosci. 2013;20:543–7.CrossRefPubMed Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA, et al. Relationship between SATB1 expression and prognosis in astrocytoma. J Clin Neurosci. 2013;20:543–7.CrossRefPubMed
13.
Zurück zum Zitat Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2012;27:143–50.CrossRefPubMed Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2012;27:143–50.CrossRefPubMed
14.
Zurück zum Zitat Endo K, Shackelford J, Aga M, Yoshizaki T, Pagano JS. Upregulation of special AT-rich-binding protein 1 by Epstein–Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013;94:507–13.CrossRefPubMedPubMedCentral Endo K, Shackelford J, Aga M, Yoshizaki T, Pagano JS. Upregulation of special AT-rich-binding protein 1 by Epstein–Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013;94:507–13.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102:1284–96.CrossRefPubMed Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102:1284–96.CrossRefPubMed
17.
Zurück zum Zitat Fang FX, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 2013;19:2331–9.CrossRefPubMedPubMedCentral Fang FX, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 2013;19:2331–9.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–93.CrossRefPubMed Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–93.CrossRefPubMed
19.
Zurück zum Zitat Mao LJ, Yang CH, Wang JQ, Li W, Wen RM, Chen JC, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013. doi:10.1186/1479-5876-11-111. Mao LJ, Yang CH, Wang JQ, Li W, Wen RM, Chen JC, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013. doi:10.​1186/​1479-5876-11-111.
20.
Zurück zum Zitat Huang B, Zhou HL, Wang XD, Liu ZL. Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 2013. doi:10.1186/1475-2867-13-8. Huang B, Zhou HL, Wang XD, Liu ZL. Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int. 2013. doi:10.​1186/​1475-2867-13-8.
22.
Zurück zum Zitat Nodin B, Hedner C, Uhlén M, Jirström K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012. doi:10.1186/1757-2215-5-24. Nodin B, Hedner C, Uhlén M, Jirström K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012. doi:10.​1186/​1757-2215-5-24.
23.
24.
Zurück zum Zitat Cheng C, Lu XM, Wang GB, Zhang L, Shu XJ, Zhu SK, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinico-pathologic features. APMIS. 2010;118:855–63.CrossRefPubMed Cheng C, Lu XM, Wang GB, Zhang L, Shu XJ, Zhu SK, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinico-pathologic features. APMIS. 2010;118:855–63.CrossRefPubMed
25.
Zurück zum Zitat Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179–89.CrossRefPubMed Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179–89.CrossRefPubMed
26.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△Ct method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△Ct method. Methods. 2001;25:402–8.CrossRefPubMed
27.
Zurück zum Zitat Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATBl in laryngeal squamous cell carcinoma. ORL. 2010;72:1–5.CrossRefPubMed Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATBl in laryngeal squamous cell carcinoma. ORL. 2010;72:1–5.CrossRefPubMed
29.
Zurück zum Zitat Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 2011;64:39–44.CrossRefPubMed Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 2011;64:39–44.CrossRefPubMed
30.
Zurück zum Zitat Jafary H, Ahmadian S, Soleimani M. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells. Tumor Biol. 2014;35:2701–10.CrossRef Jafary H, Ahmadian S, Soleimani M. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells. Tumor Biol. 2014;35:2701–10.CrossRef
31.
Zurück zum Zitat Wang T, Cui H, Ma N, Jiang YH. Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis. Oncol Lett. 2013;6:600–4.PubMedPubMedCentral Wang T, Cui H, Ma N, Jiang YH. Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis. Oncol Lett. 2013;6:600–4.PubMedPubMedCentral
32.
Zurück zum Zitat Ogata S, Takeuchi M, Fujita H, Shibata K, Okumura K, Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 Cells. Biosci Biotechnol Biochem. 2000;64:327–32.CrossRefPubMed Ogata S, Takeuchi M, Fujita H, Shibata K, Okumura K, Taguchi H. Apoptosis induced by nicotinamide-related compounds and quinolinic acid in HL-60 Cells. Biosci Biotechnol Biochem. 2000;64:327–32.CrossRefPubMed
33.
Zurück zum Zitat Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064–78.CrossRefPubMed Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064–78.CrossRefPubMed
34.
Zurück zum Zitat Han B, Luan L, Xu ZQ, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumor Biol. 2013;34:2943–9.CrossRef Han B, Luan L, Xu ZQ, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumor Biol. 2013;34:2943–9.CrossRef
35.
Zurück zum Zitat Chu SH, Zhou ZM, Feng DF, Ma YB. Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1. Mol Biol Rep. 2014;41:977–86.CrossRefPubMed Chu SH, Zhou ZM, Feng DF, Ma YB. Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1. Mol Biol Rep. 2014;41:977–86.CrossRefPubMed
Metadaten
Titel
Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression
verfasst von
Yan Zhang
Haibo Wu
Man Zhang
Yali Jiang
Weiwei Zhuo
Yong Zhang
Song Hua
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3073-3

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.